The Clinical Utilization of ApligrafT for the Healing of Chronic and Non-Chronic Wounds
Ronald G. Duff, Ph.D., Director of Clinical Research, Organogenesis, Inc.
ApligrafT (Graftskin), a biologically engineered skin substitute, is composed of human dermal fibroblasts, human
dermal kerationocytes and bovine collagen. Several clinical trials have been completed using ApligrafT as the
primary therapy for improved wound healing in venous leg ulcers, surgical exision wounds, burns and split thickness
donor graft sites. These trials have demonstrated a variety of efficacious results including an increased incidence of
healing, a decreased time to healing and an improved cosmetic outcome when compared to relevant controls. The
detailed results and interpretation of these clinical studies, as well as discussion of future clinical studies using
ApligrafT will be presented.
Workshop Sept. 17/98
ibcusa.com |
